As of April 16, 2025, Innoviva (INVA) has a market cap of $1.14 billion USD. According to our data, Innoviva is ranked No.4833 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $1.14 B |
4.66%
|
Dec 31, 2024 | $1.09 B |
8.17%
|
Dec 29, 2023 | $1.00 B |
21.06%
|
Dec 30, 2022 | $0.83 B |
-23.19%
|
Dec 31, 2021 | $1.08 B |
39.23%
|
Dec 31, 2020 | $0.78 B |
-12.50%
|
Dec 31, 2019 | $0.89 B |
-18.85%
|
Dec 31, 2018 | $1.09 B |
22.97%
|
Dec 29, 2017 | $0.89 B |
32.62%
|
Dec 30, 2016 | $0.67 B |
1.52%
|
Dec 31, 2015 | $0.66 B |
-22.29%
|
Dec 31, 2014 | $0.85 B |
-49.29%
|
Dec 31, 2013 | $1.67 B |
60.30%
|
Dec 31, 2012 | $1.04 B |
0.63%
|
Dec 30, 2011 | $1.04 B |
-11.85%
|
Dec 31, 2010 | $1.18 B |
91.81%
|
Dec 31, 2009 | $0.61 B |
5.49%
|
Dec 31, 2008 | $0.58 B |
-36.46%
|
Dec 31, 2007 | $0.92 B |
-36.87%
|
Dec 29, 2006 | $1.45 B |
37.17%
|
Dec 30, 2005 | $1.06 B |
25.81%
|
Dec 31, 2004 | $0.84 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Theravance Biopharma
TBPH
|
$0.43 B |
0.000 M
|
|
![]() Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
![]() USA
|
![]() Amgen
AMGN
|
$158.77 B |
0.132 B
|
![]() USA
|
![]() Biogen
BIIB
|
$17.12 B |
0.000 M
|
![]() USA
|
![]() Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
![]() USA
|
![]() AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
![]() USA
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
![]() USA
|
![]() Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() Novartis
NVS
|
$217.12 B |
0.003 M
|
![]() Switzerland
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
Market Cap | = | INVA Stock Price | * | INVA Shares Outstanding |
= | $18.11 | * | 62.77 M | |
= | $1.14 B |